All In Biotech

Drug Trial Radar · NCT04974749

A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry Disease

An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of REPLAGAL® in Treatment-naïve Chinese Subjects With Fabry Disease

Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

20

Actual

Start

May 1, 2022

Primary completion

Jan 3, 2024

Study completion Jan 3, 2024

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Jul 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 7 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of the study is to assess the safety of REPLAGAL. Study participants will receive REPLAGAL as an intravenous infusion every other week for 52 weeks. Participants will visit their study clinic many times throughout the study.

Conditions

  • Fabry Disease

Interventions

  • REPLAGALBiological

    REPLAGAL IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to 14 days after end of treatment (EOT) [up to Week 54]

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China

  • Xiangya Hospital, Central South University

    Changsha, China

  • West China Hospital, Sichuan University

    Chengdu, China

  • The Children's Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • Shandong Provincial Hospital

    Jinan, China

  • Ruijin Hospital, Shanghai Jiaotong Uni. School of Med.

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.